Amicus Therapeutics, Inc. Forecast, price target & analysts
Amicus Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation
Amicus Therapeutics, Inc. Classifications & Recommendation:
Amicus Therapeutics, Inc. Price Target
| Target Price | $15.05 |
| Price | $14.27 |
| Potential |
5.43%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Amicus Therapeutics, Inc. 2027 .
The average Amicus Therapeutics, Inc. target price is $15.05.
This is
5.43%
register free of charge
$23.10
61.88%
register free of charge
$14.14
0.91%
register free of charge
|
|
| A rating was issued by 17 analysts: 15 Analysts recommend Amicus Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Amicus Therapeutics, Inc. stock has an average upside potential 2027 of
5.43%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 528.30 | 641.81 |
| 32.29% | 21.49% | |
| EBITDA Margin | 8.07% | 7.28% |
| 147.23% | 9.74% | |
| Net Margin | -10.62% | -0.91% |
| 72.02% | 91.43% |
12 Analysts have issued a sales forecast Amicus Therapeutics, Inc. 2025 . The average Amicus Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Amicus Therapeutics, Inc. EBITDA forecast 2025. The average Amicus Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Amicus Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Amicus Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.18 | -0.02 |
| 64.71% | 88.89% | |
| P/E | negative | |
| EV/Sales | 7.08 |
11 Analysts have issued a Amicus Therapeutics, Inc. forecast for earnings per share. The average Amicus Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Amicus Therapeutics, Inc....
Current Amicus Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Leerink Partners |
Locked
➜
Locked
|
Locked | Dec 29 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Dec 22 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Dec 19 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Dec 19 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Dec 17 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Nov 06 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Nov 05 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Dec 29 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Dec 22 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Dec 19 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Dec 19 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Dec 17 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Nov 06 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Nov 05 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
